oxazolone and Obesity

oxazolone has been researched along with Obesity* in 1 studies

Other Studies

1 other study(ies) available for oxazolone and Obesity

ArticleYear
Design and development of 5-(4H)-oxazolones as potential inhibitors of human carbonic anhydrase VA: towards therapeutic management of diabetes and obesity.
    Journal of biomolecular structure & dynamics, 2022, Volume: 40, Issue:7

    Inhibitors of carbonic anhydrase (CAIs) hold promise for addressing various diseases, including cancer, diabetes, and other metabolic syndromes. CAV is the only isoform present in the mitochondria and is considered a potential drug target for obesity. In this work, we have developed C2, and C4 substituted oxazole-5(4H)-one derivatives as a new scaffold for the selective inhibition of human carbonic anhydrase VA (hCAVA). Synthesized compounds were characterized by

    Topics: Carbonic Anhydrase Inhibitors; Carbonic Anhydrase IX; Carbonic Anhydrases; Diabetes Mellitus; HEK293 Cells; Humans; Obesity; Oxazolone; Structure-Activity Relationship

2022